Eterna Total Assets vs Capital Stock Analysis

ERNA Stock  USD 0.31  0.02  8.24%   
Eterna Therapeutics financial indicator trend analysis is much more than just examining Eterna Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eterna Therapeutics is a good investment. Please check the relationship between Eterna Therapeutics Total Assets and its Capital Stock accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.

Total Assets vs Capital Stock

Total Assets vs Capital Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eterna Therapeutics Total Assets account and Capital Stock. At this time, the significance of the direction appears to have pay attention.
The correlation between Eterna Therapeutics' Total Assets and Capital Stock is -0.81. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Capital Stock in the same time period over historical financial statements of Eterna Therapeutics, assuming nothing else is changed. The correlation between historical values of Eterna Therapeutics' Total Assets and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Eterna Therapeutics are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Total Assets i.e., Eterna Therapeutics' Total Assets and Capital Stock go up and down completely randomly.

Correlation Coefficient

-0.81
Relationship DirectionNegative 
Relationship StrengthSignificant

Total Assets

Total assets refers to the total amount of Eterna Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Eterna Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.
Most indicators from Eterna Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eterna Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.The current year's Enterprise Value is expected to grow to about 157.2 M, whereas Tax Provision is forecasted to decline to about 25 K.
 2021 2022 2023 2024 (projected)
Interest Expense74K30K614K644.7K
Depreciation And Amortization459K497K1.1M1.1M

Eterna Therapeutics fundamental ratios Correlations

-0.120.2-0.260.92-0.23-0.30.940.080.330.960.440.880.88-0.250.7-0.710.370.50.5-0.110.520.510.54-0.220.61
-0.120.340.83-0.310.970.33-0.410.81-0.4-0.350.4-0.37-0.320.0-0.440.160.020.280.280.43-0.09-0.39-0.44-0.190.03
0.20.340.150.040.33-0.2-0.020.490.170.130.430.170.090.550.12-0.31-0.090.170.170.36-0.110.660.13-0.340.4
-0.260.830.15-0.440.880.32-0.550.63-0.48-0.520.37-0.57-0.50.03-0.660.370.220.330.330.440.03-0.56-0.370.03-0.21
0.92-0.310.04-0.44-0.4-0.320.95-0.150.250.950.060.950.98-0.390.87-0.590.250.170.17-0.320.490.530.58-0.050.65
-0.230.970.330.88-0.40.32-0.510.78-0.39-0.460.34-0.46-0.40.07-0.510.19-0.050.210.210.45-0.2-0.42-0.43-0.230.01
-0.30.33-0.20.32-0.320.32-0.330.27-0.18-0.36-0.02-0.32-0.270.09-0.250.25-0.42-0.18-0.180.39-0.31-0.52-0.82-0.2-0.1
0.94-0.41-0.02-0.550.95-0.51-0.33-0.190.420.990.220.920.92-0.310.8-0.690.280.320.32-0.280.480.520.57-0.150.54
0.080.810.490.63-0.150.780.27-0.19-0.42-0.120.54-0.16-0.130.36-0.240.1-0.20.270.270.48-0.23-0.12-0.37-0.22-0.03
0.33-0.40.17-0.480.25-0.39-0.180.42-0.420.440.270.360.290.10.27-0.830.070.290.290.070.080.450.31-0.670.49
0.96-0.350.13-0.520.95-0.46-0.360.99-0.120.440.280.940.93-0.230.81-0.730.260.340.34-0.220.450.620.58-0.20.6
0.440.40.430.370.060.34-0.020.220.540.270.280.040.00.26-0.23-0.450.370.890.890.470.210.10.04-0.440.07
0.88-0.370.17-0.570.95-0.46-0.320.92-0.160.360.940.040.98-0.290.95-0.650.070.060.06-0.240.340.690.53-0.130.73
0.88-0.320.09-0.50.98-0.4-0.270.92-0.130.290.930.00.98-0.320.94-0.610.080.050.05-0.260.350.590.51-0.140.72
-0.250.00.550.03-0.390.070.09-0.310.360.1-0.230.26-0.29-0.32-0.260.02-0.4-0.04-0.040.32-0.430.27-0.14-0.27-0.25
0.7-0.440.12-0.660.87-0.51-0.250.8-0.240.270.81-0.230.950.94-0.26-0.49-0.14-0.24-0.24-0.280.180.680.44-0.040.71
-0.710.16-0.310.37-0.590.190.25-0.690.1-0.83-0.73-0.45-0.65-0.610.02-0.49-0.13-0.45-0.45-0.09-0.14-0.56-0.420.74-0.73
0.370.02-0.090.220.25-0.05-0.420.28-0.20.070.260.370.070.08-0.4-0.14-0.130.70.7-0.240.82-0.070.560.29-0.08
0.50.280.170.330.170.21-0.180.320.270.290.340.890.060.05-0.04-0.24-0.450.71.00.160.52-0.030.23-0.280.01
0.50.280.170.330.170.21-0.180.320.270.290.340.890.060.05-0.04-0.24-0.450.71.00.160.52-0.030.23-0.280.01
-0.110.430.360.44-0.320.450.39-0.280.480.07-0.220.47-0.24-0.260.32-0.28-0.09-0.240.160.16-0.5-0.04-0.38-0.440.05
0.52-0.09-0.110.030.49-0.2-0.310.48-0.230.080.450.210.340.35-0.430.18-0.140.820.520.52-0.50.030.480.360.1
0.51-0.390.66-0.560.53-0.42-0.520.52-0.120.450.620.10.690.590.270.68-0.56-0.07-0.03-0.03-0.040.030.54-0.210.56
0.54-0.440.13-0.370.58-0.43-0.820.57-0.370.310.580.040.530.51-0.140.44-0.420.560.230.23-0.380.480.540.160.28
-0.22-0.19-0.340.03-0.05-0.23-0.2-0.15-0.22-0.67-0.2-0.44-0.13-0.14-0.27-0.040.740.29-0.28-0.28-0.440.36-0.210.16-0.49
0.610.030.4-0.210.650.01-0.10.54-0.030.490.60.070.730.72-0.250.71-0.73-0.080.010.010.050.10.560.28-0.49
Click cells to compare fundamentals

Eterna Therapeutics Account Relationship Matchups

Eterna Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets15.3M12.9M32.4M22.3M49.1M51.6M
Other Current Liab1.6M966K1.1M4.0M882K837.9K
Total Current Liabilities6.1M3.1M3.7M7.7M6.6M5.9M
Total Stockholder Equity5.1M7.7M6.5M12.1M2.2M2.1M
Non Current Assets Total9.2M11.2M13.7M8.6M39.5M41.5M
Non Currrent Assets Other2.3M453K522K5.2M120K114K
Common Stock Shares Outstanding71.9K439.7K2.2M3.1M5.3M5.0M
Liabilities And Stockholders Equity15.3M12.9M32.4M22.3M49.1M51.6M
Non Current Liabilities Total4.1M2.1M22.3M2.5M40.3M42.3M
Other Current Assets526K102K2.2M1.3M1.6M2.3M
Other Stockholder Equity136.3M(245K)166.2M177.4M189.2M131.9M
Total Liab10.2M5.2M25.9M10.2M46.9M49.2M
Total Current Assets6.1M1.7M18.8M13.7M9.6M9.8M
Short Long Term Debt Total6.1M2.9M2.7M4.1M41.8M43.9M
Property Plant And Equipment Net4.7M4.9M2.7M1.3M33.3M34.9M
Current Deferred Revenue460K76K1.2M190K218.5K207.6K
Net Debt2.8M1.3M(14.3M)(7.3M)34.3M36.0M
Retained Earnings(131.5M)(18.1M)(159.7M)(165.3M)(187.0M)(196.3M)
Accounts Payable835K1.3M1.8M1.6M1.1M764.4K
Cash3.3M1.6M17.0M11.4M7.6M6.1M
Cash And Short Term Investments3.3M1.6M17.0M11.4M7.6M6.1M
Net Receivables1.2M116K684K951K425K678.2K
Good Will1.0M667K696K2.0M2.4M1.4M
Accumulated Other Comprehensive Income200K268K245K(1K)(900.0)(855.0)
Short Term Debt3.2M799K852K2.0M4.4M4.7M
Other Liab930.4K23K48K1.6M1.9M2.0M
Net Tangible Assets7.7M5.6M23.5M10.1M11.6M12.1M
Other Assets7.3M6.4M1K5.2M4.7M4.2M
Property Plant Equipment653.8K2.7M3.2M1.3M1.5M1.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.31)
Revenue Per Share
0.03
Return On Assets
(0.29)
Return On Equity
(11.54)
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.